Loading…

Urinary biomarkers analysis as a diagnostic tool for early detection of pancreatic adenocarcinoma: Molecular quantification approach

Pancreatic ductal adenocarcinoma (PDAC) is infrequent. Currently, non-invasive biomarkers for early detection of PDAC are not accessible. Here, we intended to identify a set of urine markers able to discriminate patients with early-stage PDAC from healthy individuals. Seventy-five urine samples from...

Full description

Saved in:
Bibliographic Details
Published in:Computational biology and chemistry 2024-10, Vol.112, p.108171, Article 108171
Main Authors: Samir, Safia, El-Ashry, Mohamed, Soliman, Waleed, Hassan, Marwa
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pancreatic ductal adenocarcinoma (PDAC) is infrequent. Currently, non-invasive biomarkers for early detection of PDAC are not accessible. Here, we intended to identify a set of urine markers able to discriminate patients with early-stage PDAC from healthy individuals. Seventy-five urine samples from PDAC patients and 50 healthy controls were assayed using quantitative real-time PCR (qPCR). The chosen biomarkers were lymphatic vessel endothelial HA receptor (LYVE-1), regenerating islet-derived 1 alpha (REG1A), and trefoil factor family (TFF1). LYVE-1, REG1A, and TFF1 expression in PDAC proved to be significantly elevated compared to healthy individuals (p < 0.05). Determination of these markers' expression might be useful for early tumor diagnosis with a sensitivity of 96 %, 100 %, and 73.33 % respectively, and a specificity of 100 %, 82 %, and 100 % respectively. We have recognized three diagnostic biomarkers REG1A, TFF1, and LYVE1 that can detect patients with early-stage pancreatic cancer in non-invasive urine specimens with improved sensitivity and specificity. To the best of our knowledge, there have been no prior investigations examining the mRNA expression levels of them in urine within the Egyptian population. [Display omitted] •The LYVE1, REG1A, and TFF1 genes in urine samples can discriminate early-stage PDAC from healthy individuals.•The REG1A gene had a sensitivity and specificity of 100 % and 82 %, respectively, for detecting PDAC.•The LYVE1 gene had a sensitivity and specificity of 96 % and 100 %, respectively, for detecting PDAC.•A positive correlation was detected between the REG1A and LYVE1 genes.
ISSN:1476-9271
1476-928X
1476-928X
DOI:10.1016/j.compbiolchem.2024.108171